← board
TCRT
distress 8/10 · high distress / dilution risk$1.85-5%today-63% from 52w high
Revenue
pre-revenue
Liquidity
$0M
Runway
0.1 yrs
Shares 1y
+1013%
Price & events
-36.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-5.1%
1D
-10.6%
1W
-14.0%
1M
-33.0%
3M
-36.9%
6M
-40.3%
1Y
-51.4%
2Y
-99.4%
5Y
-99.6%
All
Overview
- Market Cap
- $45.18M
- Enterprise Value
- $44.83M
- Volume
- 3.36K
- 52 Week Range
- $1.77 – $4.99
- Total Shares
- 24.42M
- Float Shares
- 1.90M
- Short %
- 0.65%
- % Held by Insiders
- 14.51%
- % Held by Institutions
- 6.53%
- RVOL
- 0.25x
- Beta
- -1.02
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2025-12-17partnershipSettlement agreement with MD Anderson resolving unpaid invoices under 2019 R&D agreement.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.